LBPH

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for neurological diseases. The Company is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). It is focused on developing various product candidates in its pipeline, which includes bexicaserin (LP352) and LP659. The Company plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. It is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of rare neuroinflammatory conditions. The Company is conducting a Phase 1 single-ascending dose (SAD) clinical trial for LP659 in healthy volunteers.